NADH
CAS 606-68-8
Purity≥98.0%
Reduced NAD disodium salt for redox and biochemical research
Reduced Nicotinamide Adenine Dinucleotide Disodium Salt Powder (CAS 606-68-8), specification ≥98.0%. Reduced NADH in disodium-salt form, supplied as a lyophilized powder in 100 g, 500 g and 1 kg packs. Batch COA and evaluation samples are available. MOQ: 100 g. NAD+ ingredients
Quote / sample & delivery
Key Specifications
| Product Positioning | Reduced NAD disodium salt for redox and biochemical research |
| Application Scenarios | redox-enzyme reactions · NADH assay development · cofactor formulation screening |
| CAS Number | 606-68-8 |
| Purity | ≥98.0% |
| Molecular Formula | C₂₁H₂₇N₇O₁₄P₂·2Na |
| Molecular Weight | 707.40 g/mol |
| Appearance | White to off-white lyophilized powder |
| Solubility | Soluble in water |
| Storage | ≤-20°C, protect from light |
| Shelf Life | 18 months |
Procurement & delivery
Supply details confirmed by intended use, volume and target market
NADH disodium salt is the reduced, disodium form of nicotinamide adenine dinucleotide (NAD+), a pyridine dinucleotide coenzyme present in virtually all living cells, where it serves as the principal hydride/electron carrier in cellular redox metabolism. It is identified by CAS 606-68-8, molecular formula C21H27N7O14P2·2Na, and MW 707.40 g/mol, and occurs naturally in vivo as it cycles continuously with NAD+ during glycolysis, the citric acid cycle, and oxidative phosphorylation. Commercial bulk NADH is not built up from petrochemical feedstocks by classical organic synthesis; it is produced biotechnologically — NAD+ is generated by microbial fermentation, then converted to the reduced NADH form under controlled biocatalytic conditions, before being purified, salt-formed with sodium, and lyophilized into a stable powder suitable for supplement, research, and diagnostic-reagent applications.
High, Verified Purity
Assayed at ≥98.0% purity by HPLC against a reference standard, with each production batch accompanied by a certificate of analysis for buyer verification.
Synthetic Biology-Based Production
Produced on a synthetic biology and enzymatic conversion platform rather than uncontrolled extraction, giving tighter batch-to-batch consistency in yield and impurity profile.
Stable Lyophilized Powder
Supplied as a white to off-white lyophilized powder that is soluble in water, facilitating handling, weighing, and downstream formulation.
Full Contaminant Screening
Every batch is screened for heavy metals (Pb, Hg, Cd, As) and microbial limits (total plate count, yeast/mold, E. coli, Salmonella) to support food, supplement, and lab-reagent use.
Flexible Bulk & OEM Supply
Available in flexible bulk quantities with OEM/private-label packaging options, backed by an ISO-certified production and quality system.
Test items, specifications and results for the listed batch are shown here. View or request a COA in the quality documents section.
Batch No.
PGNADH-260522
Test date
2026-05-22
Specification
In-house
Pack size
1 kg, 5 kg/carton
Storage
≤-20°C, protect from light
Conclusion
Conforms
| Test Item | Specification | Result |
|---|---|---|
| Appearance | Yellow or pale yellow powder | Pale yellow powder |
| Identification | Retention time of main peak is consistent | Complies |
| Solubility | ≥100 mg/ml | Complies |
| Purity | ≥95.0% | 98.3% |
| Assay (dry basis) | ≥95.0% | 98.1% |
| Loss on drying | ≤8% | 7.18% |
| pH | 7.0–10.0 | 9.3 |
| Lead (Pb) | ≤0.5 ppm | Complies |
| Mercury (Hg) | ≤0.5 ppm | Complies |
| Cadmium (Cd) | ≤0.5 ppm | Complies |
| Arsenic (As) | ≤0.5 ppm | Complies |
| Total microbial count | ≤500 CFU/g | <10 |
| Coliform | ≤0.92 MPN/g | Complies |
| Mold and yeast | ≤50 CFU/g | Complies |
| Staphylococcus aureus | 0/25 g | Complies |
| Salmonella | 0/25 g | Complies |
View an available COA in the quality documents section. Check the document for its product form and batch; request a signed COA for your purchasing or shipment batch separately.
Hard capsules
Powders
Softgels
Tablets
Sublingual tablets
Oral dissolving films
Qualify reduced NADH disodium assay and water; do not calculate loading with NAD⁺ or free-form molar mass.
98.3%
Purity
98.1%
Assay (dry basis)
PGNADH-260522 · Results apply to this lot; interpret purity, assay and water on their respective bases.
Composition candidates, processing sequences and tests support pilot design. Confirm candidate excipients and processes using this material in the actual finished formulation.
Application examples follow the materials, formats and findings actually studied. Combination studies, single-ingredient studies, commercial precedents and development candidates are distinguished.
NADH supplies a reduced cofactor, while Q10 participates in electron transfer. A combined enteric-tablet study offers a practical reference for pairing a reduced ingredient with a lipophilic partner.
Show research and formulation insights +Hide details −Combination / selection rationale: NADH supplies a reduced cofactor, while Q10 participates in electron transfer. A combined enteric-tablet study offers a practical reference for pairing a reduced ingredient with a lipophilic partner.
Published evidence / source details: A 2021 randomized study enrolled 207 patients with ME/CFS for eight weeks of supplementation and four weeks of follow-up. Methods describe four daily enteric tablets providing 200 mg Q10 and 20 mg NADH, with PS and vitamin C also listed among excipients. Selected fatigue scores improved within the active group; several quality-of-life domains did not differ significantly between groups.
Development insights: Compare enteric tablets with conventional capsules and monitor NADH oxidation to NAD⁺ during stability testing. Assay NADH, oxidation products and Q10 separately while assessing moisture, oxygen exposure, coating and oxygen-barrier packaging. Changing PS, vitamin C or other components creates a new formulation. Total active mass alone does not determine fill feasibility.
Evidence scope: A study in a defined patient population using a formulated enteric tablet; it does not establish general anti-fatigue benefits in healthy people or two-ingredient synergy. Amounts describe the study.
2021 · Castro-Marrero et al. · CoQ10 + NADH trial · DOI 10.3390/nu13082658 ↗Combining NADH with a target dehydrogenase and regeneration module allows a screen to evaluate cofactor consumption, product formation and recycling efficiency together.
Show research and formulation insights +Hide details −Combination / selection rationale: Combining NADH with a target dehydrogenase and regeneration module allows a screen to evaluate cofactor consumption, product formation and recycling efficiency together.
Published evidence / source details: A 2023 review describes enzyme-engineering methods coupling regeneration of redox cofactors, including NAD⁺/NADH, to cellular growth. Growth differences select variants with improved cofactor turnover. This informs selection-system design rather than a universal NADH recipe for every substrate.
Development insights: Screen enzyme, substrate and cofactor concentrations with no-enzyme, no-substrate and reagent blanks. If monitoring NADH at 340 nm, check absorption interference and confirm conversion with an independent product assay. Compare regeneration modules, cycle performance and inter-lot precision.
Evidence scope: Reaction-system development guidance; intracellular growth-coupling results do not directly establish the performance of added NADH powder in a cell-free system.
2023 · Growth-coupled enzyme engineering through redox cofactor regeneration · DOI 10.1016/j.biotechadv.2023.108102 ↗Literature-Supported Research Directions
NADH is the reduced form of NAD⁺, and the NADH/NAD⁺ ratio is widely used to study dehydrogenase reactions, cellular redox state and energy metabolism. Oxidation, light exposure and extraction-related degradation should be controlled.
Citation: Lu et al. Extraction and Quantitation of Nicotinamide Adenine Dinucleotide Redox Cofactors. Antioxidants & redox signaling (2018). PMID: 28497978.View source
NADH can be used to monitor NADH-to-NAD⁺ enzymatic reactions in dehydrogenase activity, substrate-conversion and enzyme-kinetics screens. Assay platforms differ in cofactor purity, background and stability requirements.
Citation: Napper et al. Miniaturized High-Throughput Fluorescent Assay for Conversion of NAD(P)H to NAD(P). Current protocols in chemical biology (2011). PMID: 25478291.View source
Human nutrition findings for NADH depend on formulation, stability, dose and population. Fatigue, cognitive or disease-related outcomes cannot be inferred from the coenzyme mechanism alone; finished products need their own human and regulatory evidence.
Citation: Lu et al. Extraction and Quantitation of Nicotinamide Adenine Dinucleotide Redox Cofactors. Antioxidants & redox signaling (2018). PMID: 28497978.View source
Note: For ingredient R&D and scientific information; findings depend on model, dose, formulation and population and do not constitute a treatment claim or efficacy guarantee.
Lead Time
3–5business days
Standard products are generally in stock; confirm the exact lead time with us.
Minimum Order
100 g
Samples, pilot trials, and commercial volumes are supported.
Foil Pouch
Sealed, moisture-protective inner packaging
Insulated Box + Carton
For products requiring temperature-controlled transport
Bulk Shipping
Palletized and stretch-wrapped for protection
Ambient storage: foil pouch + fiber drum; temperature controlled: foil pouch + insulated box/carton. Confirm by product.
Custom packaging: Custom foil bags or HDPE drums, GMP label printing, and export documentation are available. Contact us for a quote.Images are packaging illustrations.
Certifications
Strain Fermentation
A selected microbial strain is cultured under controlled fermentation conditions to biosynthesize NAD+ as the key intermediate precursor.
Cell Harvest & Extraction
Fermentation broth is harvested and the cells are lysed to release intracellular NAD+, which is then extracted from the cellular debris.
Biocatalytic Reduction to NADH
Extracted NAD+ is converted to its reduced form, NADH, through a controlled enzymatic/biocatalytic hydride-transfer reduction step run under mild, oxygen-limited conditions to preserve the reduced cofactor.
Chromatographic Purification
The crude NADH solution is purified using ion-exchange and/or adsorption chromatography to remove residual proteins, salts, and process-related impurities.
Concentration & Salt Formation
The purified NADH solution is concentrated and reacted with a sodium source to form the stable disodium salt.
Precipitation/Crystallization
NADH disodium salt is precipitated or crystallized from the concentrate to further improve purity and remove residual mother-liquor impurities.
Lyophilization
The isolated material is freeze-dried under vacuum to yield the stable white to off-white lyophilized powder while minimizing thermal degradation of the reduced cofactor.
Milling, QC & Packaging
The lyophilized cake is milled to a uniform powder, tested against full quality specifications, and packaged under conditions that protect the product from light and moisture.
Purity is determined by high-performance liquid chromatography (HPLC), typically with UV detection near 340 nm where the reduced dinucleotide shows characteristic absorbance, run against a qualified NADH reference standard. Because NADH is redox-sensitive and can gradually oxidize back to NAD+ under heat, light, or acidic conditions, buyers should confirm the assay method, reference standard, and storage/handling conditions used for each certificate of analysis, and request batch-specific COAs before large-volume purchase.
NADH disodium salt is soluble in water, forming a clear, colorless to pale yellow solution suitable for aqueous formulation work. Because the reduced form is sensitive to oxidation, heat, and light, aqueous solutions are best prepared fresh (or used shortly after reconstitution), kept at a mildly alkaline to neutral pH, protected from direct light, and stored cold once dissolved; the dry lyophilized powder itself is comparatively easier to handle and ship at ambient or refrigerated conditions. For supplement or research formulations, buffered aqueous or lyophilized single-dose formats are commonly recommended to maintain potency through the product's shelf life.
Each production batch is tested by HPLC against a qualified reference standard, and a certificate of analysis (COA) is provided with every shipment. We recommend buyers review the COA and, where required, arrange third-party verification before large orders.
It is produced via a biotechnological route rather than classical chemical synthesis: NAD+ is generated by microbial fermentation and then converted to its reduced NADH form through a controlled enzymatic/biocatalytic reduction step, followed by purification, salt formation, and lyophilization.
Yes, it is soluble in water. Because the reduced form is sensitive to oxidation, heat, and light, we recommend preparing solutions fresh, keeping a near-neutral pH, protecting from light, and storing dissolved material cold; the dry powder is more stable for storage and transport.
Yes, small samples are available on request for quality evaluation and compatibility testing prior to committing to a bulk purchase order.
Yes, in addition to our internal COA for each batch, we support buyers sending samples to independent third-party laboratories for purity, heavy metal, and microbial testing.
Yes, we support OEM and private-label supply, including custom packaging, labeling, and documentation to meet different customer branding and regulatory requirements.
NADH disodium powder pack options are 100 g, 500 g, 1 kg. Special inner-packaging, labeling and transport requirements are agreed separately for the order.
The raw-material MOQ for NADH disodium powder is 100 g, with pack options of 100 g, 500 g, 1 kg. Orders should identify the reduced cofactor and disodium salt.
Documents are subject to product and batch availability; third-party reports are provided only when applicable.
Quality documents
The specification sheet defines acceptance limits. The COA shows actual batch results, which may vary by batch. Third-party reports are provided only for products or batches that have been independently tested.
Stable acceptance criteria · Available on request
Actual test data · Check the COA for the applicable batch
Technical Resources
NADH stability is not proven by a day-one COA alone. Before approving bulk material, review the assay method, batch age, protected storage, shipment controls and a retest plan for the actual lot.
NMN, NAD+, NR, NRHM, NMNH, and NADH are often marketed as interchangeable "NAD+ precursors," but they differ in CAS identity, purity, salt form, and cost. This is a side-by-side decision guide for picking the right form for your formulation.
"First-to-market" is a genuine selling point, but for a raw material buyer it also raises a fair question: is the supply chain behind this ingredient mature enough to support your production timeline? Here's an honest look at what makes NMNH different.
Related Products
NMN Powder (β-Nicotinamide Mononucleotide)
β-Nicotinamide Adenine Dinucleotide (NAD+) Powder
Nicotinamide Riboside Chloride Powder
Nicotinamide Riboside Hydrogen Malate Powder
Interested in NADH?
Our R&D team will respond to your inquiry or sample request within 24 hours.
Scan to add WeChat
Alex Huang · Mon–Fri 9am–6pm CST
